Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
Covid-19 could mean Medtronic loses out to Abbott, its rival in the mitral valve space.
As Smiths Group delays its split partly so it can focus on ventilator production, the US FDA grants emergency authorisation to other breathing devices to treat Covid-19.
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
For diabetes devices interoperability is key, and partnerships between Insulet, Dexcom and Abbott show that rival groups see the benefits of working together.
Medtronic has lined up a whole pipeline of new devices – and it will need them.
Heart failure data must repay Bayer and Merck & Co for taking a chance on vericiguat, and a hit for Medtronic’s renal denervation system could erase the shame of its…
Digital health is a core focus for Philips. Might more acquisitions be on the way?
The second half of 2019 saw half as many innovative medical devices approved as the first.